AccuVein’s AV300 vein illumination gadget installed in majority of U.S. Hospitals AccuVein announced today that its groundbreaking AV300 vein illumination gadget has been installed in a lot more than 275 hospitals through the entire United States, significantly less than 12 a few months after the product began delivery acheter ici . Drawing bloodstream or starting an IV on a child can be demanding because their veins may be difficult to find. We take extra treatment with our pediatric patients and the AccuVein AV300 products help us offer another personalized touch to aid in their ease and comfort, said Emily Shumway, RN, manager of pediatric providers at Scottsdale Health care Shea INFIRMARY. Related StoriesDiagnosing traumatic human brain injury through a blood check: an interview with Dr KorleyRE.WORK showcases potential technology and innovations in deep learning softwareUsing integrated molecular pathology to control incidental pancreatic cysts: an interview with Dr Ananya DasThe AccuVein AV300 helps healthcare professionals locate veins for bloodstream pull, IV infusion and bloodstream donation by projecting a pattern of light on patient’s skin that reveals the position of underlying veins.
Related StoriesStudy shows uncommon HER2 missense mutations do not spread breast cancer on the ownNew results reveal association between colorectal cancer and melanoma drug treatmentCornell biomedical engineers develop 'super natural killer cells' to destroy malignancy cells in lymph nodes We are very happy to be partnering with Accuray to progress cancer care, stated Prof. Dr. Dr. Jurgen Debus, Director of the Division of Radiation Oncology, University of Heidelberg. We have an extended history using TomoTherapy systems and have noticed the benefits they offer cancer patients, therefore we are eager to jointly explore further scientific developments. In addition to its role in advancing radiation oncology and patient care, this master study and collaboration contract bears particular significance for Accuray since it represents a chance for extended collaboration captured because of Siemens’ exit from rays therapy business.